Treatment of rapidly progressive IgA nephropathy.
Roccatello
D
D
Istituto di Nefrourologia, Università di Torino, Italia.
Ferro
M
M
Coppo
R
R
Mazzucco
G
G
Quattrocchio
G
G
Piccoli
G
G
D019268:Antibodies, Antineutrophil Cytoplasmic; D001167:Arteritis / Q000276:immunology / Q000473:pathology / Q000628:therapy; D001323:Autoantibodies / Q000276:immunology; D001706:Biopsy; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use*; D018450:Disease Progression; D005921:Glomerulonephritis / Q000276:immunology / Q000473:pathology / Q000628:therapy; D005922:Glomerulonephritis, IGA / Q000188:drug therapy / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D014890:Granulomatosis with Polyangiitis / Q000276:immunology / Q000473:pathology / Q000628:therapy; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology; D007074:Immunoglobulin G / Q000276:immunology; D007678:Kidney Glomerulus / Q000473:pathology; D008775:Methylprednisolone / Q000627:therapeutic use*; D010951:Plasma Exchange; D011241:Prednisone / Q000627:therapeutic use*; D016896:Treatment Outcome
D019268:Antibodies, Antineutrophil Cytoplasmic; D001323:Autoantibodies; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D003520:Cyclophosphamide; D011241:Prednisone; D008775:Methylprednisolone